Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo

As the validated agent for the treatment of chronic myelogenous leukemia (CML), flumatinib is a novel oral tyrosine kinase inhibitor (TKI) with higher potency and selectivity for BCR-ABL1 kinase compared to imatinib. Many patients experience aspergillosis infection and they may start using isavucona...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ya-nan, Xu, Xinhao, Nie, Jingjing, Hu, Yingying, Xu, Xuegu, Xu, Ren-ai, Du, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192561/
https://www.ncbi.nlm.nih.gov/pubmed/37214442
http://dx.doi.org/10.3389/fphar.2023.1168852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192561/
https://www.ncbi.nlm.nih.gov/pubmed/37214442
http://dx.doi.org/10.3389/fphar.2023.1168852

Ejemplares similares